SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Chris Ratcliffe — Bloomberg via Getty Images

54

Pfizer

PFE

Pfizer landed one of 2016’s most sought-after biopharma deals with its $14 billion acquisition of cancer drug maker Medivation, beating out the likes of Sanofi. In another critical business decision, the firm announced last fall that it wouldn’t split into two publicly traded companies in order to separate its generic and branded pharmaceutical businesses, raising the prospect of even more future deals. Pfizer also came under fire over drug price increases including a record $107 million fine by U.K. regulators for hiking an epilepsy treatment’s price by 2,600%.

Looking for leads, investment insights, or competitive intelligence?

CEO

Ian C. Read

CEO Title

Chairman & Chief Executive Officer

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

New York, NY

Years on Fortune 500 List

23

Employees

96,500

Profile provided by S&P Global.
Pfizer is also featured in these fortune lists
Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$52,8248.1%
Profits ($M)$7,215.03.7%
Assets ($M)$171,615
Total Stockholder Equity ($M)$59,544
Market Value — as of March 31, 2017 ($M)$203,725
Profit Ratios
Profit as % of Revenues13.7%
Profits as % of Assets4.2%
Profits as % of Stockholder Equity12.1%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)1.17
EPS % Change (from 2015)5.4%
EPS % Change (5 year annual rate)-1.6%
EPS % Change (10 year annual rate)-7.9%
Total Return
Total Return to Investors (2016)4.4%
Total Return to Investors (5 year, annualized)12.3%
Total Return to Investors (10 year, annualized)6.8%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Pfizer

The FDA Just Approved a New Pfizer Cancer Drug for a Rare, Vicious Leukemia

The therapy, Besponsa, treats a rapidly progressing version of the disease.

Read More →
Why Martin Shkreli Won’t Be the Last Pharma Bro

Price gouging isn’t going away anytime soon.

Read More →
Here's Why Shares in This Former Pfizer Target Are Tanking

AstraZeneca's big cancer immunotherapy bet is off

Read More →
3 Key Takeaways from the World's Biggest Cancer Conference

Promising cancer drugs took center stage at ASCO 2017, which wraps up Tuesday.

Read More →